Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Cash from Investing Activities (2019 - 2023)

Alx Oncology Holdings' Cash from Investing Activities history spans 5 years, with the latest figure at -$16.7 million for Q4 2023.

  • For Q4 2023, Cash from Investing Activities fell 252.31% year-over-year to -$16.7 million; the TTM value through Dec 2023 reached $44.7 million, up 118.97%, while the annual FY2025 figure was $82.6 million, 4.25% down from the prior year.
  • Cash from Investing Activities for Q4 2023 was -$16.7 million at Alx Oncology Holdings, down from $12.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $42.3 million in Q1 2023 and bottomed at -$183.9 million in Q1 2022.
  • The 5-year median for Cash from Investing Activities is -$7000.0 (2021), against an average of -$13.0 million.
  • The largest YoY upside for Cash from Investing Activities was 3540.95% in 2022 against a maximum downside of 2627342.86% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at $62000.0 in 2019, then plummeted by 117.74% to -$11000.0 in 2020, then crashed by 40972.73% to -$4.5 million in 2021, then soared by 342.19% to $10.9 million in 2022, then crashed by 252.31% to -$16.7 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Cash from Investing Activities are -$16.7 million (Q4 2023), $12.8 million (Q3 2023), and $6.2 million (Q2 2023).